IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
A phase 2/3 trial of Darovasertib, Crizotinib, Pembrolizumab in melanoma and uveal melanoma, run by IDEAYA Biosciences, active and no longer recruiting.
Overview
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma is a phase 2/3 interventional study registered as NCT05987332 by IDEAYA Biosciences, with 420 participants planned, started 2023-10-31 and due to reach its primary completion in 2027-01-15. Interventions recorded: IDE196, Crizotinib, Pembrolizumab, Ipilimumab, Nivolumab. Conditions listed: Metastatic Uveal Melanoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
Shares Darovasertib, IDEAYA Biosciences, Crizotinib, Uveal melanoma.
- Trial(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
Shares Darovasertib, IDEAYA Biosciences, Uveal melanoma, Melanoma.
- TrialNeoadjuvant Darovasertib in Primary Uveal Melanoma
Shares Darovasertib, IDEAYA Biosciences, Uveal melanoma.
- TrialStudy of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
Shares Darovasertib, IDEAYA Biosciences, Uveal melanoma.
- TrialA Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult P
Shares Uveal melanoma, Ipilimumab, Nivolumab, Melanoma.
- TrialDifferent Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma
Shares Uveal melanoma, Ipilimumab, Melanoma, Pembrolizumab.
- TrialStudy of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Shares Ipilimumab, Nivolumab, Pembrolizumab.
- TrialA Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
Shares Uveal melanoma, Melanoma, Pembrolizumab.